EpiBiologics is pioneering a novel approach to targeted protein degradation through its proprietary EpiTAC platform, which focuses on bispecific antibodies designed to selectively degrade disease-causing extracellular proteins. This innovative technology addresses a significant gap in current therapeutic strategies by targeting the 40% of the proteome that remains unaddressed by traditional intracellular degradation methods. The EpiTAC platform utilizes a unique atlas of over 270 degradation-inducing protein receptors that are expressed on the surface of various tissues and cell types, allowing for the development of tissue-selective therapies. By localizing the degradation process to disease-affected tissues, EpiTACs can effectively remove harmful proteins while sparing healthy cells, thereby enhancing therapeutic efficacy for conditions such as cancer and autoimmune disorders.

The EpiTAC platform employs multiple strategies for targeted degradation, including proteasomal and lysosomal pathways, to achieve disease-specific outcomes. Each bispecific antibody within the EpiTAC framework binds to a target protein while simultaneously engaging a selected degrader receptor, facilitating the degradation process even when the receptor is less abundant than the target. This modular approach not only amplifies the biological impact of the degradation but also allows for the potential treatment of a wide range of diseases, including oncology, immunology, and neurodegeneration. EpiBiologics is advancing its pipeline of EpiTAC therapies, with promising preclinical data supporting their effectiveness in various therapeutic areas, particularly in addressing unmet medical needs in cancer treatment.

United States

EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas. 

EpiBiologics

Company Details